Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.

Journal of clinical microbiology - 1 Sept 2006

Marcial Michelle, Lu Jing, Deeks Steven G, Ziermann Rainer, Kuritzkes Daniel R

Abstract excerpt

The performance of a gp41 assay, created using reagents designed for use with the OpenGene DNA Sequencing System, was evaluated using a panel of plasma samples obtained from enfuvirtide-naive and -experienced human immunodeficiency virus type 1-infected subjects. Resulting sequence data were highly accurate compared to a "home brew" assay and clonal sequence analysis.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Enfuvirtide
Share to HIV-1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp41

Share to HIV Fusion Inhibitors

Share to HIV Infections

Share to Microbial Sensitivity Tests

Share to Peptide Fragments

Source

Open in PubMed Open full text

Identifiers

PMID: 16954280
DOI: 10.1128/JCM.00666-06
PMCID: PMC1594677

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.PMID 16954280Read ↗

Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.Semantic proximity Read ↗

Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains.Semantic proximity Read ↗

Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.Semantic proximity Read ↗

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.Semantic proximity Read ↗

HIV-1 gp41 genetic diversity and enfuvirtide resistance-associated mutations among enfuvirtide-naïve patients in southern China.Semantic proximity Read ↗

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.Semantic proximity Read ↗

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.Semantic proximity Read ↗

Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.Semantic proximity Read ↗

Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.Semantic proximity Read ↗

Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 – 2014)Semantic proximity Read ↗

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.Semantic proximity Read ↗

Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.